Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype

NCT ID: NCT01450319

Last Updated: 2016-11-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 73 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-12-31
• Study Completion Date: 2014-12-31

Brief Summary

This national, multicenter, open-label phase 2 study without any control arm aims to evaluate the activity of cetuximab monotherapy in the treatment of refractory colorectal cancer in subjects with K-RAS mutated and FcγRIIa polymorphism tumors, in which there is no therapeutic alternative for treatment. Failure of the first and second line conventional therapeutic lines was documented.

Conditions

Colorectal Neoplasms

Keywords

K-RAS; FcγRII/IIIa genotypes; CRC; Colorectal cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cetuximab

Group Type: EXPERIMENTAL

Cetuximab

Intervention Type: DRUG

Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m\^2) every 2 weeks until disease progression, death, or consent withdrawal.

Interventions

Cetuximab

Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m\^2) every 2 weeks until disease progression, death, or consent withdrawal.

Intervention Type: DRUG

Other Intervention Names

Erbitux

Eligibility Criteria

Inclusion Criteria

• Written informed consent form signed by the subject
• Age greater than or equal to (>=) 18 years
• Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (=<) 2
• Life expectancy of greater than (>) 2 months
• Histological confirmed colorectal cancer (CRC) with mutated K-RAS and favorable genotypes (any H in FcγRIIa-131). Selection will be done only based on Cluster of differentiation (CD)32 polymorphisms
• Epidermal growth factor receptor (EGFR) expression in his/her tumor sample
• Stage 4 metastatic disease, with at least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria, documented within 28 days prior to the study inclusion
• Tumor tissue sample available for the assessment of K-RAS status and FcγRIIa (CD32) genotype
• Subject who has received at least 2 prior therapeutic lines
• Adequate bone marrow function, defined as:

• haemoglobin > 9.0 gram per deciliter (g/dL)
• platelet count >100*10^9 per liter
• absolute neutrophil count (ANC) >=1.5*10^9/Liter
• Adequate hepatic and renal function, defined as:

• Serum bilirubin =<1.5 times the upper limit of normal (ULN)
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =<2.5*ULN in absence of liver metastasis and ALT and AST =<5*ULN in the presence of liver metastasis
• Alkaline phosphatase =<2.5*ULN or =<5 in the presence of liver metastasis or =<10 in the absence of liver metastasis
• Creatinine clearance >= 50 milliliter per minute (mL/min) (according to Cockcroft and Gault formula) or serum creatinine <1.5*ULN
• Adequate recovery after recent surgery, chemotherapy or radiotherapy. Prior major surgery, chemotherapy, treatment with an investigational product or radiotherapy must have occurred at least 4 weeks before study inclusion
• Women of child-bearing potential must have a negative pregnancy test performed within 7 days prior to the study inclusion. Postmenopausal women must be amenorrheic for at least 12 months. If the risk of conception exists both male and female subjects must use effective contraception (for example, abstinence, intrauterine device (IUD), oral contraceptive, double barrier method or to be surgically sterile) since the signature of the consent form until at least 6 months after the end of treatment or end of last dose, whichever occurs first

Exclusion Criteria

• Previous treatment with monoclonal antibodies against EGFR
• Toxicity, due to previous treatment, not resolved to Grade 1 before the subject's inclusion into the study
• Clinically relevant coronary disease or myocardial infarction, unstable angina, Grade >=2 congestive cardiac insufficiency according to New York Heart Association (NYHA) within 6 months before starting the study treatment
• Clinically significant vascular disease (for example, aortic aneurysm which requires surgery, pulmonary embolism, recent peripheral arterial thrombosis) within 12 months prior to starting the study treatment
• Evidence of uncontrolled brain metastases
• History of active neurological disease
• History of uncontrolled seizures
• History of lung fibrosis, acute pulmonary damage or interstitial pneumonia
• Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C infection, or presence of severe, uncontrolled intercurrent infections or other severe uncontrolled concomitant diseases
• Current Grade >=2 (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE]) infection
• History of uncontrolled diabetes, uncontrolled hypertension or hepatic involvement
• Known or suspected allergy or hypersensitivity to cetuximab
• History of previous malignancy other than CRC occurring within 5 years before starting the study treatment, except for previously cured basal cell carcinoma of skin or carcinoma in situ of the cervix or urinary bladder treated more than 2 years before recruitment
• Participation in another treatment study with an investigational drug within the last 30 days
• Pregnancy or lactation
• Any medical, psychological, psychiatric or social uncontrolled problem which may interfere in the participation of the subject in the study or in the evaluation of the study results
• Psychological, familiar or geographic conditions not allowing the adequate follow-up and adherence to the study protocol

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Merck, S.L., Spain

INDUSTRY

Sponsor Role: collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director

Role: STUDY_DIRECTOR

Merck, S.L., Spain

Locations

Research Site

A Coruña, , Spain

Research Site

Asturias, , Spain

Research Site

Barcelona, , Spain

Research Site

Córdoba, , Spain

Research Site

Madrid, , Spain

Research Site

Navarra, , Spain

Research Site

Santiago de Compostela, , Spain

Research Site

Seville, , Spain

Research Site

Valencia, , Spain

Countries

Spain

References

Manzanares-Martin B, Cebrian Aranda A, Del Puerto-Nevado L, Gonzalez R, Solanes S, Gomez-Espana MA, Garcia-Foncillas J, Aranda E. Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes. J Immunother Cancer. 2021 Apr;9(4):e001705. doi: 10.1136/jitc-2020-001705.

Reference Type: DERIVED

PMID: 33833048 (View on PubMed)

Other Identifiers

2010-023580-18

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

EMR 062202-529

Identifier Type: -

Identifier Source: org_study_id